| 2020 |
Sato D, Takahata M, Ota M, Fukuda C, Hasegawa T, Yamamoto T, Amizuka N, Tsuda E, Okada A, Hiruma Y, Fujita R, Iwasaki N. Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats. Bone. June 2020;135:115331. |
2 |
1 |
| 2021 |
Makino A, Hasegawa T, Takagi H, Takahashi Y, Hase N, Amizuka N. Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: a comparison with teriparatide. Bone. January 2021;142:115651. |
0 |
0 |
| 2022 |
Tsuda E, Fukuda C, Okada A, Karibe T, Hiruma Y, Takagi N, Isumi Y, Yamamoto T, Hasegawa T, Uehara S, Koide M, Udagawa N, Amizuka N, Kumakura S. Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use. Bone. February 2022;155:116241. |
0 |
0 |
| 2021 |
Zhao S, Hasegawa T, Hongo H, Yamamoto T, Abe M, Yoshida T, Haraguchi M, Luiz de Freitas PH, Li M, Tei K, Amizuka N. Intermittent PTH administration increases bone-specific blood vessels and surrounding stromal cells in murine long bones. Calcif Tiss Int. March 2021;108(3):391-406. |
1 |
1 |
| 2007 |
Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. June 2007;5(6):464-475. |
103 |
102 |
| 2020 |
Hongo H, Hasegawa T, Saito M, Tsuboi K, Yamamoto T, Sasaki M, Abe M, de Freitas PHL, Yurimoto H, Udagawa N, Li M, Amizuka N. Osteocytic osteolysis in PTH-treated wild-type and Rankl−/− mice examined by transmission electron microscopy, atomic force microscopy, and isotope microscopy. J Histochem Cytochem. October 2020;68(10):651-668. |
1 |
1 |